American Association For Respiratory Care Seeks Clarification On Brovana Reimbursement
April 30, 2007 – 4:46 pm | posted in Respiratory / AsthmaAARC has contacted CMS to request clarification on their policies for the reimbursement of Brovana (arfomoterol) in the home care setting.
Brovana, a new long-acting beta agonist (LABA), has recently been introduced, but has not yet been assigned a reimbursement code for home use. Therefore, availability of the medication to patients discharged from the hospital may be limited, interrupting the continuity of care and depriving patients of an efficacious medication.
AARC has urged CMS to quickly provide clarification on the use of Brovana. "Given the current uncertainty, problems are arising concerning access to Brovana outside the hospital which poses a threat to the continuity of care for COPD patients and undermines appropriate management and control of their condition," said Sam Giordano in his letter to the Region D Medical Director.
The AARC asks for immediate clarification on the policy and then a swift evaluation and assignment of a J code for the medication.
In the letter, AARC points out that Brovana is decreasing the frequency of treatment, as physicians quickly use Brovana as one of the front line treatments for patients with COPD.
AARC will be following this issue and will alert members when CMS has issued a response to our letter or a clarification on the home use of Brovana.
You must be logged in to post a comment.